Effect of olmesartan compared with candesartan on home blood pressure and prognostic makers of subsequent cardiovascular events in patients with essential hypertension: a single center, prospective, randomized, and open-labeled trial

Effect of olmesartan compared with candesartan on home blood pressure and prognostic makers of subsequent cardiovascular events in patients with essential hypertension: a single center, prospective, randomized, and open-labeled trial - Effect of olmesartan on home blood pressure and prognostic makers of cardiovascular events in patients with essential hypertension: a single center randomized trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006904

Enrollment

Registered

2011-12-21

Start date

2012-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential hypertension

Interventions

Olmesartan treatment group

After the randomization, candesartan (4mg or 8mg/day) is switched to the treatment with olmesartan (10mg or 20mg/day) for 12 months Candesartan treatment group

After the randomization, candesartan (4mg or 8mg/day) treatment will be continued for 12 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Stable hypertension patients treated with candesartan for more than one year

Exclusion criteria

Exclusion criteria: 1. Atrial fibrillation or atrial flutter 2. History of congestive heart failure (NYHA functional class II or severer) within 6 months of enrollment 3. History of myocardial infarction, unstable angina, PTCA or CABG within 6 months of enrollment 4. History of PTA or lower extremities bypass surgery within 6 months of enrollment 5. History of cerebrovascular diseases within 6 months of enrollment 6. Plan to be performed PTCA or CABG 7. Congenital heart disease 8. sBP >=180 mmHg or dBP >=110 mmHg in a sitting position 9. Left ventricular ejection fraction <30% 10. Pregnancy or possible pregnancy 11. Hepatic dysfunction (AST and/or ALT >100 IU/l) 12. Renal dysfunction (serum creatinine >= 1.5 mg/dl) 13. Uncontrolled type 2 diabetes (HbA1c >= 8.0%) 14. Hypertensive retinopathy with hemorrhage, oozing or papilledema 15. Hyper potassium (serum potassium >= 5.5 mEq/L) 16. History of severe side effect of ARB 17. Current or history of participation (within 6 months of enrollment) in another clinical trial 18. Patients who are otherwise judged inappropriate for inclusion by the investigator

Design outcomes

Primary

Measure	Time frame
home blood pressure in early morning, left ventricular mass index on echocardiography, serum cystatin C level	—

Secondary

Measure	Time frame
plasma BNP level, urinary potassium, urinary micro albumin, arterial stiffness	—

Countries

Japan

Contacts

Public ContactMisako Ito

Chiba Kensei Hospital Clinical Research Center

043-239-2212

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026